Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

TNFRSF8 expression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

TNFRSF8 expression	Lymphoma	TNFRSF8 expression	Lymphoma	SGN-35C Sensitive: D – Preclinical ASH 2023 - 4 weeks (New D) SGN-35C Sensitive : D ASH 2023 - 4wk	SGN-35C Sensitive: D – Preclinical ASH 2023 - 4 weeks SGN-35C Sensitive : D ASH 2023 - 4 weeks - (New D)
TNFRSF8 expression	Peripheral T-cell Lymphoma	TNFRSF8 expression	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
TNFRSF8 expression	Cutaneous T-cell Lymphoma	TNFRSF8 expression	Cutaneous T-cell Lymphoma	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B
TNFRSF8 expression	T Cell Non-Hodgkin Lymphoma	TNFRSF8 expression	T Cell Non-Hodgkin Lymphoma	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B
TNFRSF8 expression	Acute Myelogenous Leukemia	TNFRSF8 expression	Acute Myelogenous Leukemia	brentuximab vedotin Sensitive: C1 - Off-label brentuximab vedotin Sensitive : C1	brentuximab vedotin Sensitive: C1 - Off-label brentuximab vedotin Sensitive : C1
TNFRSF8 expression	Diffuse Large B Cell Lymphoma	TNFRSF8 expression	Diffuse Large B Cell Lymphoma	rituximab + brentuximab vedotin Sensitive: C3 – Early Trials rituximab + brentuximab vedotin Sensitive : C3	rituximab + brentuximab vedotin Sensitive: C3 – Early Trials rituximab + brentuximab vedotin Sensitive : C3
TNFRSF8 expression	Peripheral T-cell Lymphoma	TNFRSF8 expression	Peripheral T-cell Lymphoma	CHEP-BV Sensitive: C3 – Early Trials CHEP-BV Sensitive : C3	CHEP-BV Sensitive: C3 – Early Trials CHEP-BV Sensitive : C3
TNFRSF8 expression	Peripheral T-cell Lymphoma	TNFRSF8 expression	Peripheral T-cell Lymphoma	AFM13 Sensitive: C3 – Early Trials AFM13 Sensitive : C3	AFM13 Sensitive: C3 – Early Trials AFM13 Sensitive : C3
TNFRSF8 expression	Cutaneous T-cell Lymphoma	TNFRSF8 expression	Cutaneous T-cell Lymphoma	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D
TNFRSF8 expression	Peripheral T-cell Lymphoma	TNFRSF8 expression	Peripheral T-cell Lymphoma	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D
TNFRSF8 expression	Hodgkin Lymphoma	TNFRSF8 expression	Hodgkin Lymphoma	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D
TNFRSF8 expression	Hematological Malignancies	TNFRSF8 expression	Hematological Malignancies	F0002-ADC Sensitive: D – Preclinical F0002-ADC Sensitive : D	F0002-ADC Sensitive: D – Preclinical F0002-ADC Sensitive : D